"Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new projects of strategic interest to Sanofi."
Q32 Bio, a biotechnology company developing biologics to restore healthy immune regulation.
i2O Therapeutics is a biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs.
Veralox Therapeutics Inc is developing first-in-class therapeutics targeting 12-Lipoxygenase (12-LOX) to bring new treatments to patients with rare blood disorders and diabetes.
Imbria Pharmaceuticals is advancing the science of cellular metabolism to create novel and transformative medicines.
Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulator agencies.
Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases.
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs.
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
We are a healthcare technology and services company that provides scalable innovative contracting solutions with its blockchain-based platform.
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases.
We help health plans and employers tackle type 2 diabetes and heart disease in the most engaging, effective, and scalable way possible.
Evidation Health helps healthcare companies quantify behavior-driven outcomes in the digital era, with real life data from connected patients.
Science 37 has created a new clinical trial operating model – the metasite™ – that unlocks access so researchers can find the right patients, and patients can find the right trials.
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding.
Navitor is pioneering the selective targeting of mTORC1 activation to develop a new class of medicines for age-related diseases to improve human health.
Ovid Therapeutics Inc. is a privately-held, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain.
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer.
Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases.
Immune Design is a public immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease.
Common Sensing is introducing GoCap, a safer and more convenient way for diabetics to track and dose insulin.